Some extended-release formulations of the diabetes drug metformin contained levels of a nitrosamine impurity falling above the US Food and Drug Administration’s (FDA’s) acceptable intake limit, ...
Two manufacturers have announced voluntary recalls of metformin formulations containing elevated levels of a potential carcinogen. Granules Pharmaceuticals, based in Virginia, has issued a recall for ...
Lupin Pharmaceuticals Inc. is voluntarily recalling Metformin Hydrochloride Extended-Release Tablets USP (generic equivalent of Fortamet®), 500mg, lot G901203 to the consumer level. FDA analysis ...
Metformin, a drug prescribed to tens of millions of people with type 2 diabetes, is producing measurable shifts in molecular ...